Breaking Down Revenue Trends: Dr. Reddy's Laboratories Limited vs Xencor, Inc.

Comparing Revenue Growth: Dr. Reddy's vs. Xencor

__timestampDr. Reddy's Laboratories LimitedXencor, Inc.
Wednesday, January 1, 20141321700000009520000
Thursday, January 1, 201514818900000027762000
Friday, January 1, 201615470800000087520000
Sunday, January 1, 201714080900000035711000
Monday, January 1, 201814202800000040603000
Tuesday, January 1, 2019153851000000156700000
Wednesday, January 1, 2020174600000000122694000
Friday, January 1, 2021189722000000275111000
Saturday, January 1, 2022214391000000164579000
Sunday, January 1, 2023245879000000168338000
Monday, January 1, 2024279164000000
Loading chart...

Unlocking the unknown

Revenue Trends: A Tale of Two Companies

In the competitive landscape of the pharmaceutical and biotechnology sectors, Dr. Reddy's Laboratories Limited and Xencor, Inc. present a fascinating study in contrasts. Over the past decade, Dr. Reddy's has demonstrated a robust growth trajectory, with revenue increasing by approximately 111% from 2014 to 2023. This growth underscores the company's strategic expansion and market penetration. In contrast, Xencor, Inc., a smaller player in the biotech field, has shown a more volatile revenue pattern. Despite a significant spike in 2021, where revenue peaked at nearly 275% of its 2014 value, the company has experienced fluctuations, reflecting the inherent risks and rewards of biotech innovation. Notably, data for 2024 is incomplete, leaving room for speculation on future trends. This comparison highlights the diverse challenges and opportunities faced by companies in these dynamic industries.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025